CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

human insulin

Last Updated: December 22, 2020
Result type: Reports
Project Number: SR0672-000
Product Line: Reimbursement Review

Generic Name: human insulin

Brand Name: Entuzity KwikPen

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Diabetes mellitus

Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

Manufacturer Requested Reimbursement Criteria1: To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: December 22, 2020

Call for patient/clinician input closed: February 22, 2021

Anticipated Date: January 27, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback